Compare Abeona Therapeutics Inc (ABEO) vs Chubb Ltd (CB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Chubb Ltd — how do they compare? Abeona Therapeutics Inc trades at $6.75 (market cap $373.32M), while Chubb Ltd trades at $356.55 (market cap $139.36B). The key difference: Chubb Ltd is far larger — about 373.3× Abeona Therapeutics Inc's market cap, and Chubb Ltd pays a 1.14% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | CB | |
|---|---|---|
Market Cap | $373.32M | $139.36B |
Sector | Health | Financials |
52-Week High | $7.23 | $361.17 |
52-Week Low | $4.17 | $265.99 |
Enterprise Value | $228.22M | $160.41B |
Dividend Yield | — | 1.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Chubb (CB) trades at $359.30, down 0.52% on the day but near its 52-week high, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with consistent earnings beats, revenue growth from $59.78B in 2025 to projected $61.2B in 2026, and a net income margin of 18.46%. Recent news highlights premium growth and disciplined underwriting as key strengths.
Outlook remains positive with analyst consensus favoring Buy ratings (52.38%) and a price target of $341.90, though risks include catastrophe losses and softer commercial pricing. The stock's valuation at P/E 12.61 offers value, but investors should monitor Q2 2026 earnings due July 22, 2026, for confirmation of growth trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Chubb Ltd
ACE acquired Chubb in the first quarter of 2016 and assumed the Chubb name. The combination makes the new Chubb one of the largest domestic property and casualty insurers, with operations in 54 countries spanning commercial and personal P&C insurance, reinsurance, and life insurance.
Read more on CB →
